Literature DB >> 14501450

Progressive late-onset sensorineural hearing loss and vestibular impairment with vertigo (DFNA9/COCH): longitudinal analyses in a belgian family.

Francois X Lemaire1, Louw Feenstra, Patrick L M Huygen, Erik Fransen, Koen Devriendt, Guy Van Camp, Greet Vantrappen, Cor W R J Cremers, Phillip A Wackym, John C Koss.   

Abstract

OBJECTIVE: To evaluate audiometric and vestibular signs and symptoms in a new DFNA9 family.
SETTING: Tertiary referral centers.
METHODS: A multigeneration Belgian family with late-onset progressive sensorineural hearing loss and concomitant ves-tibular impairment with an autosomal dominant pattern of inheritance underwent clinical and genetic evaluation. Medical history was recorded. Blood samples were taken for genetic linkage and mutation analyses. Pure-tone audiometry, speech audiometry and vestibular examinations were performed. Onset and progression in hearing impairment were evaluated with linear regression analysis of longitudinal threshold-on-age data.
RESULTS: Linkage to DFNA9 was confirmed and mutation analysis revealed a P51S mutation in the COCH gene. Several patients had a Ménière's-like presentation. All patients developed late-onset progressive sensorineural hearing loss eventually leading to severe deafness and vestibular failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501450     DOI: 10.1097/00129492-200309000-00009

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  Mutation in the COCH gene is associated with superior semicircular canal dehiscence.

Authors:  Michael S Hildebrand; Dylan Tack; Adam Deluca; In Ae Hur; Jana M Van Rybroek; Sarah J McMordie; Ann Muilenburg; David P Hoskinson; Guy Van Camp; Myles L Pensak; Ian S Storper; Patrick L M Huygen; Thomas L Casavant; Richard J H Smith
Journal:  Am J Med Genet A       Date:  2009-02       Impact factor: 2.802

2.  Identification of a rare COCH mutation by whole-exome sequencing : Implications for personalized therapeutic rehabilitation in an Austrian family with non-syndromic autosomal dominant late-onset hearing loss.

Authors:  Thomas Parzefall; Alexandra Frohne; Martin Koenighofer; Andreas Kirchnawy; Berthold Streubel; Christian Schoefer; Wolfgang Gstoettner; Klemens Frei; Trevor Lucas
Journal:  Wien Klin Wochenschr       Date:  2017-07-21       Impact factor: 1.704

Review 3.  Genotype-Phenotype Correlations of Pathogenic COCH Variants in DFNA9: A HuGE Systematic Review and Audiometric Meta-Analysis.

Authors:  Sybren M M Robijn; Jeroen J Smits; Kadriye Sezer; Patrick L M Huygen; Andy J Beynon; Erwin van Wijk; Hannie Kremer; Erik de Vrieze; Cornelis P Lanting; Ronald J E Pennings
Journal:  Biomolecules       Date:  2022-01-27

4.  Does Otovestibular Loss in the Autosomal Dominant Disorder DFNA9 Have an Impact of on Cognition? A Systematic Review.

Authors:  Jonas De Belder; Stijn Matthysen; Annes J Claes; Griet Mertens; Paul Van de Heyning; Vincent Van Rompaey
Journal:  Front Neurosci       Date:  2018-01-09       Impact factor: 4.677

5.  Genotype-phenotype Correlation Study in a Large Series of Patients Carrying the p.Pro51Ser (p.P51S) Variant in COCH (DFNA9): Part I-A Cross-sectional Study of Hearing Function in 111 Carriers.

Authors:  Sebastien P F JanssensdeVarebeke; Julie Moyaert; Erik Fransen; Britt Bulen; Celine Neesen; Katrien Devroye; Raymond van de Berg; Ronald J E Pennings; Vedat Topsakal; Olivier Vanderveken; Guy Van Camp; Vincent Van Rompaey
Journal:  Ear Hear       Date:  2021 Nov-Dec 01       Impact factor: 3.570

6.  Genotype-Phenotype Correlation Study in a Large Series of Patients Carrying the p.Pro51Ser (p.P51S) Variant in COCH (DFNA9) Part II: A Prospective Cross-Sectional Study of the Vestibular Phenotype in 111 Carriers.

Authors:  Sebastien P F JanssensdeVarebeke; Julie Moyaert; Erik Fransen; Britt Bulen; Celine Neesen; Katrien Devroye; Raymond van de Berg; Ronald J E Pennings; Vedat Topsakal; Olivier Vanderveken; Guy Van Camp; Vincent Van Rompaey
Journal:  Ear Hear       Date:  2021 Nov-Dec 01       Impact factor: 3.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.